Keyword: Charles Grassley
Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.
Lawmakers on both sides of the aisle refuse to let go of the proposal to force drug pricing into consumer advertising, but they're not the only ones.
Citing Mylan's EpiPen, two senators introduced a bill cracking down on drug misclassifications that cost Medicaid millions in underpaid rebates.
Sticker prices in drug ads might be off the table again, thanks to some in the U.S. House of Representatives.
What do polarized senators dislike more than their partisan opponents? Pharma advertising, apparently.
Think President Trump's bid to slap price tags on drug ads is all talk? Think again. In recent days, the idea has gained steam—and bipartisan backing.
After pharma suffered an unexpected loss in this year's budget deal, the industry sees an opportunity to get some relief.
Congress hasn't made progress on pricing reform, but a group of lawmakers are pushing to reduce waste in pharmaceuticals.
It didn't take long for Congress to push back at Allergan's first-of-a-kind patent deal with the Saint Regis Mohawk Tribe.
Mylan has finished a settlement with the Department of Justice for $465 million relating to EpiPen’s misclassification on Medicaid.